leadf
logo-loader
viewRedx Pharma PLC

Redx Pharma's chief medical officer talks Phase II study plans for lead programme RXC004

Redx Pharma's (LON:REDX) chief medical officer Andrew Saunders recaps on its lead clinical programme RXC004. He says clinical evaluation of the drug in patients with advanced solid tumours in a phase 1 study is expected to complete in the second half of this year however recruitment into the trial has been paused due to COVID-19. Saunders adds that, once they're able to, the plans are to initiate Phase 2 studies before the end of the year in both mono-therapy as well as studying the combination of RXC004 with a checkpoint inhibitor.

Quick facts: Redx Pharma PLC

Price: 67.5 GBX

AIM:REDX
Market: AIM
Market Cap: £131.79 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Redx Pharma PLC named herein, including the promotion by the Company of Redx Pharma PLC in any Content on the Site, the Company receives from...

FOR OUR FULL DISCLAIMER CLICK HERE

Redx Pharma PLC in a great place to move forward after Astra deal says CEO

Lisa Anson, chief executive of Redx Pharma PLC (LON:REDX) says the out-license deal with AstraZeneca for its fibrosis porcupine inhibitor is good news for the company and also for people suffering from the condition. Using a porcupine inhibitor in lung-scarring diseases such as IPF is a novel...

on 4/8/20

2 min read